Does low stool butyrate reduce regulatory immune signaling and anti-inflammatory gene expression in the intestinal mucosa?

Butyrate, a key microbial short-chain fatty acid, is vital for preserving intestinal immune tolerance. When stool butyrate levels fall, the intestinal mucosa undergoes profound epigenetic and receptor-level changes that undermine regulatory immune responses.

Receptor and epigenetic mechanisms

• Diminished GPCR activation: Under normal conditions, butyrate acts as a key ligand for G-protein coupled receptors (GPCRs). Low butyrate reduces GPR109A signaling on dendritic cells and macrophages, which impairs retinaldehyde dehydrogenase induction and subsequent naïve T-cell conversion to peripheral regulatory T-cells (Tregs). It also reduces GPR43 signaling on lamina propria CD4+ T cells, which typically suppresses pro-inflammatory proliferation.
• Loss of HDAC inhibition: Butyrate serves as a class I histone deacetylase (HDAC) inhibitor. When concentrations fall below the critical physiological threshold of 0.1–0.5 mM, reduced HDAC inhibition prevents histone H3 acetylation at the Foxp3 promoter and conserved non-coding sequence regions, destabilizing Treg lineage commitment.

Impact on anti-inflammatory gene expression

• Downregulated gene transcription: This dual mechanistic failure directly impairs the transcription of essential anti-inflammatory mediators. Without adequate butyrate, the mucosal tissue experiences reduced expression of Foxp3, IL-10, and TGF-β across intestinal epithelial cells, dendritic cells, and CD4+ T cells.
• Pro-inflammatory susceptibility: The resulting reduction in mucosal IL-10-mediated signaling and Treg homeostasis compromises the overall regulatory network, leaving the mucosal microenvironment highly vulnerable to unchecked inflammation.

Bottom line

• Low stool butyrate directly drives intestinal immune dysregulation by impairing GPCR signaling (GPR109A/GPR43) and limiting HDAC-mediated histone H3 acetylation at the Foxp3 locus, which downregulates mucosal IL-10, TGF-β, and Foxp3 expression and compromises mucosal tolerance.